Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Yarrow Bioscience, Inc.MNLO · Entity 6871 | Director | April 03, 2020 | April 07, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Yarrow Bioscience, Inc.
Report date April 03, 2020 · Filed April 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 201,410 |
Ending reported balance
After 2020-04-03 transaction · row 3
2 source rows · reconciled sequenceRow 1 · 2020-04-03 · Grant · Acquired 63,844 · Balance 130,107 F1: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2) F2: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing. Row 3 · 2020-04-03 · Grant · Acquired 71,303 · Balance 201,410 F4: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo. F1: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2) F2: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 328,609 |
Reported balance
After 2020-04-03 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-04-03 · Grant · Acquired 220,496 · Balance 328,609 F1: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2) F2: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing. F3: Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch. |
Filing footnotes · ownership attribution and instrument terms
F1: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2)
F2: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing.
F3: Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch.
F4: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Foamix Pharmaceuticals Ltd.
Report date March 09, 2020 · Filed March 11, 2020
Section 16 reporting ended · disclosed 2020-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 241,516 |
Reported balance
After 2020-03-09 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2020-03-09 · Disposition to issuer · Disposed 52,842 · Balance 241,516 F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2020-03-09 · Disposition to issuer · Disposed 59,016 · Balance 0 F4: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee footnote | 59,016 |
Reported balance
After 2020-03-09 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-03-09 · Disposition to issuer · Disposed 182,500 · Balance 59,016 F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. F3: Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2024-12-29 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-03-09 · Disposition to issuer · Disposed 27,000 · Balance 0 F6: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F5: The Options vested over a period of three years from December 29, 2014 (33.3% on each anniversary of such date). |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.69 · Expires 2027-07-13 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-03-09 · Disposition to issuer · Disposed 82,153 · Balance 0 F6: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F7: The ordinary shares underlying this option vest over a period of four years (25% on July 13, 2017 and 6.25% every three months thereafter) ending July 13, 2021. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.02 · Expires 2028-05-08 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-03-09 · Disposition to issuer · Disposed 49,766 · Balance 0 F6: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F8: The ordinary shares underlying these options vested over a 12 month period, in equal, quarterly installments, ending May 8, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2)
F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement.
F3: Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch.
F4: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR.
F5: The Options vested over a period of three years from December 29, 2014 (33.3% on each anniversary of such date).
F6: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options.
F7: The ordinary shares underlying this option vest over a period of four years (25% on July 13, 2017 and 6.25% every three months thereafter) ending July 13, 2021.
F8: The ordinary shares underlying these options vested over a 12 month period, in equal, quarterly installments, ending May 8, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2020 Filed Apr 7, 2020 21:22 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 71,303 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023807 · doc4.xml · nonDerivative · entry 3 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,410 F4 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo. F1 · price: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2) F2 · price: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:22 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 220,496 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023807 · doc4.xml · nonDerivative · entry 2 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 328,609 F1 · price: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2) F2 · price: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing. F3 · ownership.nature: Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:22 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 63,844 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023807 · doc4.xml · nonDerivative · entry 1 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,107 F1 · price: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2) F2 · price: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:57 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 29,481 | Not disclosed Strike: $8.48 | Not disclosed |
DisclosureSEC source: 0001209191-20-018227 · doc4.xml · derivative · entry 6 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,481 Underlying: Common Stock · 29,481 shares Expires 2028-05-08 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:57 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 48,667 | Not disclosed Strike: $7.92 | Not disclosed |
DisclosureSEC source: 0001209191-20-018227 · doc4.xml · derivative · entry 5 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,667 Underlying: Common Stock · 48,667 shares Expires 2027-07-13 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. F4 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on July 13, 2017 and 6.25% every three months thereafter) ending July 13, 2021. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:57 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 15,994 | Not disclosed Strike: $9.93 | Not disclosed |
DisclosureSEC source: 0001209191-20-018227 · doc4.xml · derivative · entry 4 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,994 Underlying: Common Stock · 15,994 shares Expires 2024-12-29 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:57 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 34,960 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018227 · doc4.xml · nonDerivative · entry 3 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,263 F3 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo. F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:57 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 108,113 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018227 · doc4.xml · nonDerivative · entry 2 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 108,113 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. F2 · ownership.nature: Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:57 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 31,303 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018227 · doc4.xml · nonDerivative · entry 1 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,303 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:39 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 49,766 | Not disclosed Strike: $5.02 | Not disclosed |
DisclosureSEC source: 0001209191-20-018197 · doc4.xml · derivative · entry 6 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 49,766 shares Expires 2028-05-08 F6 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F8 · derivative.exercise_date: The ordinary shares underlying these options vested over a 12 month period, in equal, quarterly installments, ending May 8, 2019. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:39 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 82,153 | Not disclosed Strike: $4.69 | Not disclosed |
DisclosureSEC source: 0001209191-20-018197 · doc4.xml · derivative · entry 5 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 82,153 shares Expires 2027-07-13 F6 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F7 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on July 13, 2017 and 6.25% every three months thereafter) ending July 13, 2021. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:39 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 27,000 | Not disclosed Strike: $5.88 | Not disclosed |
DisclosureSEC source: 0001209191-20-018197 · doc4.xml · derivative · entry 4 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 27,000 shares Expires 2024-12-29 F6 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F5 · derivative.exercise_date: The Options vested over a period of three years from December 29, 2014 (33.3% on each anniversary of such date). Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:39 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOrdinary Shares | 59,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018197 · doc4.xml · nonDerivative · entry 3 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · price: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:39 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOrdinary Shares | 182,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018197 · doc4.xml · nonDerivative · entry 2 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 59,016 F1 · price: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2 · price: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. F3 · ownership.nature: Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:39 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOrdinary Shares | 52,842 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018197 · doc4.xml · nonDerivative · entry 1 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,516 F1 · price: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2 · price: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 16:32 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOrdinary Shares | 42,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015195 · doc4.xml · nonDerivative · entry 1 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,858 F1 · security: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F2 · shares: The ordinary shares underlying this restricted share unit award vest over a 12 month period, in equal, quarterly installments, ending February 27, 2021. Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 16:32 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Exercise / conversionOptions · Derivative | 32,500 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001209191-19-055210 · doc4.xml · derivative · entry 3 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Ordinary Shares · 32,500 shares Expires 2019-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch. Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 16:32 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Exercise / conversionOrdinary Shares | 32,500 | $0.62 | $20,150.00 |
DisclosureSEC source: 0001209191-19-055210 · doc4.xml · nonDerivative · entry 1 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 182,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 16:11 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Exercise / conversionOptions · Derivative | 90,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001209191-19-053413 · doc4.xml · derivative · entry 3 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 32,500 Underlying: Ordinary Shares · 90,000 shares Expires 2019-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 16:11 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Exercise / conversionOrdinary Shares | 90,000 | $0.62 | $55,800.00 |
DisclosureSEC source: 0001209191-19-053413 · doc4.xml · nonDerivative · entry 1 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 150,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 14:59 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Exercise / conversionOptions · Derivative | 60,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001178913-19-002190 · zk1923414.xml · derivative · entry 3 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 122,500 Underlying: Ordinary Shares · 60,000 shares Expires 2019-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 14:59 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Exercise / conversionOrdinary Shares | 60,000 | $0.62 | $37,200.00 |
DisclosureSEC source: 0001178913-19-002190 · zk1923414.xml · nonDerivative · entry 1 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch. Read SEC document |
| May 16, 2019 Filed May 20, 2019 18:34 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOrdinary Shares | 56,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-031529 · doc4.xml · nonDerivative · entry 1 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,365 F1 · security: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F2 · shares: The ordinary shares underlying this restricted share unit award vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020. Read SEC document |
| July 13, 2018 Filed Jul 13, 2018 16:08 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Exercise / conversionRestricted Share Units · Derivative | 1,616 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001178913-18-002082 · zk1821887.xml · derivative · entry 2 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,616 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F3 · derivative.exercise_date: The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on July 13, 2018 and 6.25% every three months thereafter) ending July 13, 2021. F3 · derivative.expiration_date: The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on July 13, 2018 and 6.25% every three months thereafter) ending July 13, 2021. F4 · balance_after: This class of restricted share units is included in Column 5 of Table I above. Read SEC document |
| July 13, 2018 Filed Jul 13, 2018 16:08 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Exercise / conversionOrdinary Shares | 1,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-18-002082 · zk1821887.xml · nonDerivative · entry 1 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F2 · balance_after: The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 6,508 ordinary shares previously reported in Table I of the reporting person's Form 4 (ii) 1,616 ordinary shares underlying restricted share units that vested on July 13, 2018 (iii) 4,850 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security. Read SEC document |
| May 13, 2018 Filed May 31, 2018 16:51 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | OtherWarrants (right to buy) · Derivative | 6,224 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001178913-18-001826 · zk1821767.xml · derivative · entry 3 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,224 shares Expires 2018-05-13 Read SEC document |
| May 13, 2018 Filed May 31, 2018 16:51 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | SaleOrdinary Shares | 6,164 | $5.09 | $31,368.60 |
DisclosureSEC source: 0001178913-18-001826 · zk1821767.xml · nonDerivative · entry 2 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,508 F1 · kind: On May 13, 2018, warrants held by Mr. Hirsch for the purchase of up to 6,224 ordinary shares of the Issuer for $5.04 per share were automatically exercised on a net-issuance (cashless) basis upon their expiration, in accordance with their terms. This cashless exercise resulted in the Issuer withholding 6,164 of the warrant shares to pay the exercise price and issuing to Mr. Hirsch the remaining 60 shares. Read SEC document |
| May 13, 2018 Filed May 31, 2018 16:51 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | OtherOrdinary Shares | 6,224 | $5.04 | $31,368.96 |
DisclosureSEC source: 0001178913-18-001826 · zk1821767.xml · nonDerivative · entry 1 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,672 Read SEC document |
| May 08, 2018 Filed May 10, 2018 17:36 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOptions · Derivative | 49,766 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001178913-18-001603 · zk1821663.xml · derivative · entry 1 Hirsch Stanley · CIK 0001727864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,766 Underlying: Ordinary Shares · 49,766 shares Expires 2028-05-08 F1 · security: Each option represents a contingent right to purchase one ordinary share of the issuer. F2 · derivative.exercise_date: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 8, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.